Success for individualised cancer vaccineGerman biotech company Biontech AG has published positive clinical results for its individualised cancer vaccine Ivac mutanome in patients with late-stage melanoma. more ➔
Seventure debuts in Japan with microbiome... Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life … more ➔
Noxxon/MSD start testing of immunoncologic...Last December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off … more ➔
Exscientia inks €37m contract with GSKBritish pharma giant GlaxoSmithKline has secured access to Ex Scientia Ltd (Exscientia)s artificial intelligence (AI)-driven drug discovery platform. more ➔
Breaking therapy resistance of follicular...Swiss researchers have found a way to prevent the multiple disease relapses after responses to follicular lymphoma therapy. more ➔
AML: Cellectis testing allogenic CAR-T cel... Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia. more ➔
Diabetes: J&J and Seventure Partners...European venture capitalist Seventure Partners and Johnson & Johnson have invested US$12m in Israel-based DayTwo. Based on HbA1c, lifestyle factors and genetic analysis of the individual microbiome, … more ➔
€66m Life Sciences Fund focused on Germa...Venture Capitalist Biogeneration Ventures has exceeded the target size of its life sciences fund BGV III through investments from the European Investment Banks InnovFin Equity Facility and the Dutch … more ➔
CHMP recommends several biologicsThe European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has recommended two antivirals, one biosimilar and two cancer meds for approval at its June meeting. more ➔
Roches lampalizumab halts geographic atr...A publication in Science Translational Medicine shows that Roche has a rising star in the 15 million patient market of age-related macular degeneration (AMD). In a Phase II trial, US and German researchers … more ➔
